Renal effects of ularitide in patients with decompensated heart failure

Background: Renal function frequently deteriorates in decompensated heart failure (DHF) patients, and one determinant is reduced renal blood flow. This may, in part, result from low cardiac output (CO), reduced mean arterial pressure (MAP), and venous congestion. The combined impact of both venous congestion (elevated right atrial pressure [RAP]) and low MAP are reflected by a reduced pressure gradient MAP-RAP. This study investigated the renal effects of ularitide, a synthetic version of the renal natriuretic peptide urodilatin in DHF patients. Methods: In SIRIUS II, a double-blind phase II trial, 221 patients hospitalized for DHF (with dyspnea at rest or minimal activity, cardiac index ≤2.5 L/min per square meter, and pulmonary artery wedge pressure ≥18 mm Hg) were randomized to a single 24-hour infusion of ularitide (7.5, 15, or 30 ng/kg per minute) or placebo added to standard therapy. Results: Estimated glomerular filtration rate, serum creatinine, creatinine clearance, and blood urea nitrogen (BUN) were not impaired by ularitide throughout infusion and during a 2-day follow-up period. At 24 hours, 15 ng/kg per minute ularitide reduced BUN levels (-4.07 ± 12.30 vs -0.20 ± 7.50 for placebo, P < .05). Ularitide at 15 and 30 ng/kg per minute rapidly elevated CO with sustained effects. Although 15 ng/kg per minute ularitide preserved the pressure gradient MAP-RAP, 30 ng/kg per minute ularitide reduced MAP-RAP by -7.8 ± 10.6 mm Hg vs -2.4 ± 9.8 mm Hg for placebo (P < .01, at 6 hours). A strong inverse correlation between MAP-RAP and BUN levels (Corr = -0.50579, P = .00015) was observed with 15 ng/kg per minute ularitide. Conclusions: Single 24-hour infusions of ularitide at 15 ng/kg per minute preserved short-term renal function in DHF patients possibly by both elevating CO and maintaining the MAP-RAP pressure gradient. © 2008 Mosby, Inc. All rights reserved.

Lüss H.1, 2 , Mitrovic V.3 , Seferovic P.M.4 , Simeunovic D.4 , Ristić A.D.4 , Moiseyev V.S. 5 , Forssmann W.-G.6 , Hamdy A.M.7 , Meyer M.1
Номер выпуска
  • 1 Cardiopep Pharma GmbH, Hannover, Germany
  • 2 Institut für Pharmakologie und Toxikologie, Universitätsklinikum Münster, Münster, Germany
  • 3 Kerckhoff-Klinik, Bad Nauheim, Germany
  • 4 University Medical Center of Serbia, Belgrade, Serbia
  • 5 Russian Peoples Friendship University, Moscow, Russian Federation
  • 6 Division of Experimental and Clinical Peptide Research, Hannover Medical School, Hannover, Germany
  • 7 PDL Biopharma Inc., Fremont, CA, United States
Ключевые слова
creatinine; furosemide; loop diuretic agent; placebo; urodilatin; adult; article; clinical trial; controlled clinical trial; controlled study; correlation analysis; creatinine blood level; creatinine clearance; cystitis; double blind procedure; drug effect; female; follow up; glomerulus filtration rate; heart failure; heart index; hematuria; human; hypotension; kidney failure; kidney function; lung wedge pressure; major clinical study; male; multicenter study; phase 2 clinical trial; pressure gradient; priority journal; randomized controlled trial; side effect; statistical significance; urea nitrogen blood level; urine volume; Aged; Atrial Natriuretic Factor; Creatinine; Diuretics; Double-Blind Method; Female; Glomerular Filtration Rate; Heart Failure; Humans; Infusions, Intravenous; Kidney; Male; Middle Aged; Peptide Fragments; Severity of Illness Index
Дата создания
Дата изменения
Постоянная ссылка

Другие записи

Cornélissen G., Halberg F., Singh R.B., Manukyan L., Khalilov E., Muller C., Quadens O., Barreto L.M., Wang Z., Wu J., Zhao Z., Dusek J., Fiser B., Homolka P., Prikryl P., Siegelova J., Strestik J., Amory-Mazaudier C., Berger S., Hecht K., Jozsa R., Pati A.K., Singh R.K., Carandente F., Maggioni C., Laffi G., Perfetto F., Rostagno C., Tarquini R., Salti R., Fujimura A., Kumagai Y., Mitsutake G., Otsuka K., Watanabe Y., Weydahl A., Chirinos J., Blank M., Denisova O., Breus T.K., Blagonravov M.B., Chibisov S.M., Masalov A., Malkova I., Mitish M., Syutkina E.V., Turti T., Zaslavskaya R.M., Gvozdjakova A., Zeman M., Revilla M., Ulmer W., Valenzi V., Bogdanov V., Gorgo Y., Delyukov A., Wilson D., Simpson H., Hillman D., Sothern R.B., Bingham C., Hawkins D., Holte J., Johnson D., Adams C., Beaty L., Nolley E., Engebretson M., Bakken E., Holley D., Sundaram S., De Prins J., Delcourt A., Deruyck C., Toussaint G., De La Peña S.S., Mikulecky Sr.M.
World Heart Journal. Том 1. 2008. С. 15-21